HDAC9 and cancer: Trichostatin A (TSA) was one of the first HDAC inhibitors to be discovered and although its anti-cancer properties are well documented, its sub-optimal in vivo stability has made it less attractive for use as a chronically administered anti-cancer drug [31], [32].